CN Patent

CN101778855A — 替诺福韦酯半富马酸共晶体

Assigned to ULTIMORPHIX TECHNOLOGIES BV · Expires 2010-07-14 · 16y expired

What this patent protects

本发明提供被称为共晶体TDFA 2∶1的富马酸替诺福韦酯(富马酸替诺福韦酯)的新晶型，其制备方法及其在药物应用中(特别是在抗HIV药物中)的应用。晶型TDFA 2∶1可以与其它抗HIV药物组合使用，所述抗HIV药物例如依法韦仑、恩曲他滨、利托那韦和/或TMC114。

USPTO Abstract

本发明提供被称为共晶体TDFA 2∶1的富马酸替诺福韦酯(富马酸替诺福韦酯)的新晶型，其制备方法及其在药物应用中(特别是在抗HIV药物中)的应用。晶型TDFA 2∶1可以与其它抗HIV药物组合使用，所述抗HIV药物例如依法韦仑、恩曲他滨、利托那韦和/或TMC114。

Drugs covered by this patent

Patent Metadata

Patent number
CN101778855A
Jurisdiction
CN
Classification
—
Expires
2010-07-14
Drug substance claim
No
Drug product claim
No
Assignee
ULTIMORPHIX TECHNOLOGIES BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.